{"entity":{"id":"advesya","kind":"company","name":"Advesya","aka":["Advesya SAS"],"tldr":"Advesya develops treatments aimed at IL-1RAP, a protein found on leukaemia cells. Its lead treatment, a CAR-T therapy made from the patient's own immune cells, is being tested in acute myeloid leukaemia that has come back or not responded.","summary":"Advesya is a French and Swiss clinical-stage biotech company founded in 2020, according to the company, as a spin-out from the French Blood Institute (EFS) in Besançon by Christophe Ferrand and Marina Deschamps, and seeded by Jeito in 2022. Its work targets IL-1RAP, an antigen it describes as upregulated in several cancers and autoimmune conditions. CCTx-001 is an IL-1RAP-directed autologous CAR-T therapy built from CD8 and CD4 T cells, assessed in a phase 1/2 adaptive trial in relapsed or refractory acute myeloid leukaemia (NCT06281847) with sites listed in France, Germany, Spain and Sweden. ADV-101 is a first-in-class ADC made of a humanised IgG1 anti-IL-1RAP antibody carrying a topoisomerase I inhibitor payload through a cleavable linker. Its first registered cancer trial, NCT06281847, was posted on ClinicalTrials.gov in February 2024.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://advesya.com/"},{"label":"Our science: CCTx-001 and ADV-101","url":"https://advesya.com/our-science/"},{"label":"ClinicalTrials.gov: phase 1/2 trial of CCTx-001 in AML (NCT06281847)","url":"https://clinicaltrials.gov/study/NCT06281847"}],"tags":[],"related":[],"cancers":["aml"],"sections":["cell-therapy","adcs"],"technologies":["car-t","adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Headquarters city not stated on the website; Besançon is where the company was spun out of the French Blood Institute (EFS).","Headquarters city not stated on the website; the company calls itself French/Swiss and the registry sponsor is Advesya SAS, so country is FR.","IL-1RAP has no target id in the corpus, so no target is linked.","No financing amount is stated; Jeito is named only as the 2022 seed investor.","The website's news page returned HTTP 404 on 29 October 2026; company and science pages read the same day."],"hq":"Besançon","country":"FR","companyType":"cell-therapy","website":"https://advesya.com/","founded":2020,"stage":"startup","investors":["jeito-capital"],"funding":[]},"route":"/companies/advesya/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"},{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"company":[{"id":"jeito-capital","kind":"company","name":"Jeito Capital","route":"/companies/jeito-capital/"}]}}